Continue reading this on our app for a better experience

Open in App
Home Capital Results

Q&M reports 46% lower earnings of $5.3 mil in 1HFY2023 as medical lab segment sees lower demand for Covid-19 testing

Felicia Tan
Felicia Tan • 2 min read
Q&M reports 46% lower earnings of $5.3 mil in 1HFY2023 as medical lab segment sees lower demand for Covid-19 testing
One of Q&M Dental Group’s clinics at City Square. Photo: Albert Chua/The Edge Singapore
Font Resizer
Share to Whatsapp
Share to Facebook
Share to LinkedIn
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

Q&M Dental Group QC7 -

has reported earnings of $5.3 million in the 1HFY2023 ended June 30, 46% lower than the earnings of $9.8 million in the same period the year before.

The lower earnings were mainly due to the lower revenue from the group’s “other business”, which fell by 46.6% y-o-y to $3.8 million. The group’s other business mainly refers to its medical laboratory, which was impacted by the lower demand for Covid-19 testing.

Revenue for the group’s core healthcare business dipped by 1% y-o-y to $83.3 million as higher revenue contribution from its clinics in Singapore was offset by .

Overall revenue fell by 4% y-o-y to $87.1 million.

Total ebitda fell by 16% y-o-y to $18.5 million while ebitda for the group’s core healthcare business dropped by 11% y-o-y to $18.2 million.

Earnings per share (EPS) on a fully diluted basis stood at 0.56 cents.

See also: Mapletree Investments reports $577.2 mil loss for FY2024 from non-operational losses

A first interim dividend of 0.16 cent per share has been declared for the period, down from the 0.4 cent dividend the year before. The dividend is payable on Sept 13.

Cash and cash equivalents as at June 30 stood at $33.4 million.

“The continual resilience of Q&M’s core healthcare business is well appreciated by investors and reflects the group’s well-established foundations. Further, we will focus on organic growth following significant expansion of our dental clinic network across Singapore and Malaysia in 2022. We will continue to invest in technology and implement strategies that will enable us to further optimise productivity across our clinic network,” says Dr Ng Chin Siau, group CEO of Q&M.

See also: Seatrium reports net order book of $25.8 bil in 1QFY2024 business update

Looking ahead, the group says it aims to build a “strong platform” for its future growth in five key ways. They are: building strong foundations by strengthening its basis, improving efficiency by reducing costs and wastage, developing its medical laboratory business, expanding its brand at home and overseas and being committed to its community through charity work.

Shares in Q&M closed flat at 29 cents on Aug 14.

Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
© 2024 The Edge Publishing Pte Ltd. All rights reserved.